Amedisys (NASDAQ:AMED) edged lower by 1.2% after a judge tentatively set a date for the Dep. of Justice's challenge of ...
A trial between the Justice Department and UnitedHealth Group Inc. over its proposed purchase of Amedisys Inc. will take place in October 2025, a Maryland federal judge ruled Thursday.
UnitedHealth Group and Amedisys outlined plans to divest a significant number of home health and hospice locations as they ...
UnitedHealth Group said in a court filing it is working with Amedisys to identify potential buyers for at least 128 home ...
Recent developments in the legal battle over the planned $3.3 billion UnitedHealth Group (NYSE: UHG) acquisition of Amedisys (Nasdaq: AMED) have moved the ...
The healthcare industry is poised for significant growth owing to increased operational efficiency with the addition of ...
UnitedHealth Group has withdrawn its motion to dismiss the Justice Department’s ongoing antitrust challenge to a proposed ...
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. BATON ROUGE, La., ...
8d
Zacks.com on MSNAmedisys (AMED) Earnings Expected to Grow: Should You Buy?Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth Group said its motion to dismiss the DOJ lawsuit was moot after the agency cited which regions would be impacted by the Amedisys acquisition.
Shares of Amedisys, Inc. (NASDAQ:AMED – Get Free Report) have been given a consensus rating of “Hold” by the six research firms that are presently covering the company, Ratings reports. Five ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results